BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonis...

2025-12-08

BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Advanced Neuroscience and Metabolic Research

Executive Summary: BIIE 0246 is a well-characterized neuropeptide Y Y2 receptor (Y2R) antagonist with high selectivity and nanomolar affinity (IC₅₀ 3.3 nM; K_i 8–15 nM) (APExBIO). It robustly blocks presynaptic Y2R-mediated inhibition, impacting neuropeptide Y (NPY) signaling in both central and peripheral nervous systems (Fan et al., 2024). BIIE 0246 fully inhibits PYY_3-36-induced colon contraction and significantly attenuates feeding suppression by PYY_3-36 in rodents (Related Review). Behavioral assays confirm anxiolytic-like effects, making it a standard for dissecting NPY-driven satiety and anxiety mechanisms. Strict storage and solubility parameters ensure reliability for research use only.

Biological Rationale

The neuropeptide Y (NPY) system plays a critical regulatory role in energy homeostasis, anxiety, and cardiovascular function (Fan et al., 2024). Y2 receptors (Y2R) are G-protein-coupled receptors (GPCRs) expressed both centrally (especially in the hippocampus and hypothalamus) and peripherally. These receptors mediate presynaptic inhibition of NPY release, modulating neural excitability and neurotransmitter balance. In metabolic regulation, Y2R activation by peptides such as PYY_3-36 contributes to post-prandial satiety and reduction in food intake. Recent studies have linked the NPY system and Y2R signaling to the adipose-neural axis, which influences not only feeding but also cardiac arrhythmogenesis, as elevated NPY levels and receptor interactions are implicated in epicardial adipose tissue-driven cardiac events (Fan et al., 2024).

Mechanism of Action of BIIE 0246

BIIE 0246 is a highly selective, competitive antagonist of the NPY Y2 receptor. It binds to Y2R with an IC₅₀ of 3.3 nM and K_i values between 8–15 nM for PYY_3-36 binding sites (APExBIO). Mechanistic studies in rat hippocampal slices demonstrate that BIIE 0246 blocks Y2R-mediated presynaptic inhibition, preventing NPY from reducing afterdischarge activity and population excitatory postsynaptic potentials. In peripheral models, BIIE 0246 abolishes PYY_3-36-induced colon contraction, confirming Y2R antagonism at smooth muscle (In-depth Mechanistic Review). This blockade translates to behavioral outcomes: administration of BIIE 0246 reverses PYY_3-36-induced reduction in feeding and produces anxiolytic-like effects in elevated plus-maze assays in rodents. The compound does not significantly interact with other NPY receptor subtypes (e.g., Y1, Y5) at relevant concentrations, ensuring target specificity.

Evidence & Benchmarks

BIIE 0246 exhibits high affinity for Y2R: IC₅₀ = 3.3 nM, K_i = 8–15 nM, quantified in radioligand binding assays (APExBIO datasheet, product page).
Blocks presynaptic Y2R-mediated inhibition in rat hippocampal slices, measured as suppressed NPY-induced reduction in afterdischarge activity (Methodology Review).
Completely inhibits PYY_3-36-induced contraction in rat colon at nanomolar concentrations (Comparative Analysis).
Attenuates PYY_3-36-induced reduction in food intake in rodent models, linking Y2R antagonism with feeding behavior modulation (Fan et al., 2024).
Reduces anxiety-like behavior in the elevated plus-maze, demonstrating anxiolytic-like effect in validated behavioral assays (Strategic Review).
Standard storage (4°C, desiccated) and solubility (67.2 mg/ml in DMSO, 23.55 mg/ml in ethanol) ensure high reproducibility in experimental protocols (APExBIO).

Applications, Limits & Misconceptions

BIIE 0246 is widely used for:

Dissecting the NPY signaling pathway in neural, metabolic, and cardiovascular models (Related Article; this article provides new data-driven context on benchmark concentrations and storage).
Studying post-prandial satiety by antagonizing Y2R-mediated feeding suppression.
Evaluating anxiolytic-like effects in established behavioral paradigms.
Investigating the adipose-neural axis in cardiac arrhythmias, complementing Y1R antagonist studies (Fan et al., 2024).

BIIE 0246 is supplied by APExBIO (SKU: B6836) as a white solid, molecular weight 896.06, formula C₄₉H₅₇N₁₁O₆. It is recommended for research use only and not for diagnostic or medical purposes.

Common Pitfalls or Misconceptions

BIIE 0246 is not a pan-NPY antagonist; it is selective for Y2R and does not significantly inhibit Y1, Y4, or Y5 receptors at standard concentrations.
It is not suitable for in vivo diagnostic or therapeutic use; research applications only.
Long-term storage of reconstituted solutions is not recommended due to stability loss.
Effects observed in rodent models may not directly translate to human physiology without further validation.
BIIE 0246 does not antagonize leptin or other non-NPY pathways implicated in adipose-neural axis signaling.

Workflow Integration & Parameters

Preparation: Dissolve BIIE 0246 in DMSO (up to 67.2 mg/ml) or ethanol (up to 23.55 mg/ml) immediately prior to use. Avoid prolonged storage of solutions.
Storage: Store powder at 4°C, desiccated, in a light-protected vial (product page).
Experimental concentrations: Typical working range is 1–100 nM for in vitro systems and 0.1–1 mg/kg (i.p. or s.c.) for rodent in vivo studies; always titrate for the specific model.
Controls: Use vehicle-only and positive controls (e.g., PYY_3-36) to validate Y2R antagonism.
Readouts: Quantify effects on feeding, anxiety (elevated plus-maze), synaptic activity (hippocampal slices), or smooth muscle contraction as appropriate.

For a comprehensive workflow and troubleshooting guide, see the detailed methodology in this benchmark review (this article provides updated vendor specifications and clarifies stability constraints).

Conclusion & Outlook

BIIE 0246, available as the B6836 kit from APExBIO, is a gold-standard, selective Y2 receptor antagonist for dissecting neuropeptide Y signaling in neuroscience, metabolic, and cardiovascular research. Its robust specificity, validated in vivo and in vitro efficacy, and established storage/use protocols make it indispensable for studies of presynaptic inhibitory effect blockade, feeding modulation, anxiety, and adipose-neural axis function. Ongoing research, especially into the intersection of NPY signaling and cardiac arrhythmias, is likely to expand its translational relevance (Fan et al., 2024). For detailed product data and usage protocols, refer to the official APExBIO BIIE 0246 product page.